{"filing":{"accession_number":"0001213900-26-096784","cik":"0001840563","ticker":"ELAB","company_name":"PMGC Holdings Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-27","primary_document":"ea0304419-8k_pmgchold.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/ea0304419-8k_pmgchold.htm"},"events":[{"id":31385,"run_id":28791,"accession_number":"0001213900-26-096784","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NorthStrive Biosciences (PMGC subsidiary) entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on August 27, 2026, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead compound nomination in Cardiac Diseases and Obesity. The amendment updates program scope, IP framework, field of use definitions, financial terms, and grants a right of first refusal across the cardiometabolic field.","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34241,"accession_number":"0001213900-26-096784","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NorthStrive Biosciences (PMGC subsidiary) entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on August 27, 2026, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead compound nomination in Cardiac Diseases and Obesity. The amendment updates program scope, IP framework, field of use definitions, and financial terms. While this is a material definitive agreement under Item 1.01, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), nor does it fit other specific event categories. This is a material strategic partnership expansion and development program advancement that would affect investor assessment of the company's drug discovery pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34242,"accession_number":"0001213900-26-096784","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material modification to security holder rights under Item 3.03, but the substantive content (via incorporated Item 5.03 reference and the press release exhibit) concerns a First Amendment to a Development and License Agreement with Yuva Biosciences that expands the scope of an AI-driven drug discovery program, clarifies field-of-use definitions, and grants a right of first refusal across the cardiometabolic field. This is a material operational/strategic partnership amendment rather than a direct modification of security holder voting or economic rights. The Item 3.03 reference appears to be a technical cross-reference; the core event is the expanded development program and amended commercial terms with a strategic partner.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34244,"accession_number":"0001213900-26-096784","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NorthStrive Biosciences (PMGC subsidiary) executed a First Amendment to its Development and License Agreement with Yuva Biosciences, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead nomination in cardiac disease and obesity. The amendment updates program scope, IP framework, field of use definitions, and financial terms, and grants a right of first refusal across the broader cardiometabolic field. This is a material strategic partnership amendment advancing the company's drug discovery pipeline, but does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/operational events—it is a material contract/partnership milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31386,"run_id":28791,"accession_number":"0001213900-26-096784","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"The Company's Articles of Incorporation were amended to increase authorized shares from an unstated prior amount to 1,500,000,000 shares (1 billion common, 500 million preferred), approved by shareholders at 60.34% voting power. This is a routine capital structure authorization with no disclosed imminent issuance or specific use of the additional shares.","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34243,"accession_number":"0001213900-26-096784","item_number":"5.03","item_title":"Amendment to Articles of Incorporation","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"The Item 5.03 disclosure concerns an amendment to the Company's Articles of Incorporation increasing authorized shares from an unstated prior amount to 1,500,000,000 shares (1 billion common, 500 million preferred), approved by shareholders at 60.34% voting power. This is a routine governance/capital structure matter. While share authorization increases can signal dilution risk, the filing itself contains no disclosure of an imminent issuance, offering, or specific use of the additional shares—only the mechanical authorization increase. The supplemental press release (EX-99.1) addresses a separate operational matter (an amendment to a development agreement with Yuva Biosciences) and does not materially alter the governance classification of Item 5.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34241,"accession_number":"0001213900-26-096784","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NorthStrive Biosciences (PMGC subsidiary) entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on August 27, 2026, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead compound nomination in Cardiac Diseases and Obesity. The amendment updates program scope, IP framework, field of use definitions, and financial terms. While this is a material definitive agreement under Item 1.01, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), nor does it fit other specific event categories. This is a material strategic partnership expansion and development program advancement that would affect investor assessment of the company's drug discovery pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02"},{"id":34242,"accession_number":"0001213900-26-096784","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material modification to security holder rights under Item 3.03, but the substantive content (via incorporated Item 5.03 reference and the press release exhibit) concerns a First Amendment to a Development and License Agreement with Yuva Biosciences that expands the scope of an AI-driven drug discovery program, clarifies field-of-use definitions, and grants a right of first refusal across the cardiometabolic field. This is a material operational/strategic partnership amendment rather than a direct modification of security holder voting or economic rights. The Item 3.03 reference appears to be a technical cross-reference; the core event is the expanded development program and amended commercial terms with a strategic partner.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02"},{"id":34243,"accession_number":"0001213900-26-096784","item_number":"5.03","item_title":"Amendment to Articles of Incorporation","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"The Item 5.03 disclosure concerns an amendment to the Company's Articles of Incorporation increasing authorized shares from an unstated prior amount to 1,500,000,000 shares (1 billion common, 500 million preferred), approved by shareholders at 60.34% voting power. This is a routine governance/capital structure matter. While share authorization increases can signal dilution risk, the filing itself contains no disclosure of an imminent issuance, offering, or specific use of the additional shares—only the mechanical authorization increase. The supplemental press release (EX-99.1) addresses a separate operational matter (an amendment to a development agreement with Yuva Biosciences) and does not materially alter the governance classification of Item 5.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02"},{"id":34244,"accession_number":"0001213900-26-096784","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NorthStrive Biosciences (PMGC subsidiary) executed a First Amendment to its Development and License Agreement with Yuva Biosciences, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead nomination in cardiac disease and obesity. The amendment updates program scope, IP framework, field of use definitions, and financial terms, and grants a right of first refusal across the broader cardiometabolic field. This is a material strategic partnership amendment advancing the company's drug discovery pipeline, but does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/operational events—it is a material contract/partnership milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:06:48.469480+00:00","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-09-02"}]}